Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

taVNS for Speech and Language Recovery in Aphasia

NCT: NCT07563387 · ENROLLING_BY_INVITATION

NCT IDNCT07563387
StatusENROLLING_BY_INVITATION
Start Date2026-01-01
Completion2028-01-01

Brief Summary

The goal of this research study is to evaluate a novel approach to improving speech recovery in those with acquired apraxia of speech. We will enroll participants with apraxia of speech resulting from stroke or brain injury to complete several tasks and intervention. Testing will take place four times over the course of the study and intervention will take place 5 days a week for 16 weeks. Overall, you can expect to spend up to 17 weeks participating in this study.

Frequently Asked Questions

What is taVNS for Speech and Language Recovery in Aphasia?

taVNS for Speech and Language Recovery in Aphasia is a clinical trial registered under NCT07563387. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT07563387?

The current status of NCT07563387 (taVNS for Speech and Language Recovery in Aphasia) is: ENROLLING_BY_INVITATION.

When did taVNS for Speech and Language Recovery in Aphasia start?

taVNS for Speech and Language Recovery in Aphasia started on 2026-01-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.